Evidence map›Paper›PMID 38480700›Full record

ArticleNPJ Parkinson's disease2024

Disease progression strikingly differs in research and real-world Parkinson's populations.

Brett K Beaulieu-Jones, Francesca Frau, Sylvie Bozzi, Karen J Chandross, M Judith Peterschmitt, Caroline Cohen, Catherine Coulovrat, Dinesh Kumar, Mark J Kruger, Scott L Lipnick and 3 more

Open access · goldAbstract read
In one paragraph

Article in NPJ Parkinson's disease, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
8.5field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Prasinezumab: A Bayesian Perspective on Its Efficacy.Movement disorders : official journal of the Movement Disorder Society · 2025
    Article
  15. Validation of Parkinson's Disease Ascertainment in the Veterans Administration Electronic Medical Record.Movement disorders : official journal of the Movement Disorder Society · 2025
    Article
  16. Article
  17. Article
  18. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 3 countries.

Brett K Beaulieu-JonesDepartment of Biomedical Informatics, Harvard Medical School, Boston, MA, 02115, USA. beaulieujones@uchicago.edu.ORCID http://orcid.org/0000-0002-6700-1468
Francesca FrauSanofi R&D, Data and Data Science, Frankfurt, Germany.
Sylvie BozziSanofi Health Economics and Value Assessment, Sanofi, Paris, France.
Karen J ChandrossSanofi R&D, Bridgewater, NJ, USA.ORCID http://orcid.org/0000-0002-1346-2162
M Judith PeterschmittSanofi Genzyme, Clinical Development Neurology, Cambridge, MA, USA.
Caroline CohenSanofi R&D, Paris, France.
Catherine CoulovratSanofi Translational Sciences, Framingham, MA, 01701, USA.
Dinesh KumarSanofi Translational Sciences, Framingham, MA, 01701, USA.
Mark J KrugerSanofi Genzyme, Clinical Development Neurology, Cambridge, MA, USA.
Scott L LipnickDepartment of Biomedical Informatics, Harvard Medical School, Boston, MA, 02115, USA.
Lane FitzsimmonsDepartment of Biomedical Informatics, Harvard Medical School, Boston, MA, 02115, USA.
Isaac S KohaneDepartment of Biomedical Informatics, Harvard Medical School, Boston, MA, 02115, USA.
Clemens R ScherzerAPDA Center for Advanced Parkinson Research of Harvard Medical School and Brigham and Women's Hospital, Boston, MA, 02115, USA. clemens.scherzer@yale.edu.ORCID http://orcid.org/0000-0002-0567-9193
Harvard University · USSanofi (United States) · USBrigham and Women's Hospital · USSanofi (France) · FRSanofi (Germany) · DE

Funding

Genome-Wide Prediction of Dementia in Parkinson's DiseaseR01NS115144 · NINDS · YALE UNIVERSITY · PI SCHERZER, CLEMENS R · 2019 to 2025
$4.4M
GBA pathway markers for Lewy body dementiasU01NS100603 · NINDS · BRIGHAM AND WOMEN'S HOSPITAL · PI SCHERZER, CLEMENS R · 2016 to 2020
$2.9M
Parkinson Disease: Predicting the FutureU01NS095736 · NINDS · BRIGHAM AND WOMEN'S HOSPITAL · PI SCHERZER, CLEMENS R · 2016 to 2018
$2.1M
Characterizing Population Differences between Clinical Trial and Real World PopulationsR00NS114850 · NINDS · UNIVERSITY OF CHICAGO · PI BEAULIEU-JONES, BRETT K · 2023 to 2025
$740k
Characterizing Population Differences between Clinical Trial and Real World PopulationsK99NS114850 · NINDS · HARVARD MEDICAL SCHOOL · PI BEAULIEU-JONES, BRETT K · 2021 to 2022
$186k
NINDS NIH HHS K99 NS114850NINDS NIH HHS R00 NS114850NINDS NIH HHS R01 NS115144NINDS NIH HHS U01 NS095736NINDS NIH HHS U01 NS100603
6 · The paper itself

Abstract

Characterization of Parkinson's disease (PD) progression using real-world evidence could guide clinical trial design and identify subpopulations. Efforts to curate research populations, the increasing availability of real-world data, and advances in natural language processing, particularly large language models, allow for a more granular comparison of populations than previously possible. This study includes two research populations and two real-world data-derived (RWD) populations. The research populations are the Harvard Biomarkers Study (HBS, N = 935), a longitudinal biomarkers cohort study with in-person structured study visits; and Fox Insights (N = 36,660), an online self-survey-based research study of the Michael J. Fox Foundation. Real-world cohorts are the Optum Integrated Claims-electronic health records (N = 157,475), representing wide-scale linked medical and claims data and de-identified data from Mass General Brigham (MGB, N = 22,949), an academic hospital system. Structured, de-identified electronic health records data at MGB are supplemented using a manually validated natural language processing with a large language model to extract measurements of PD progression. Motor and cognitive progression scores change more rapidly in MGB than HBS (median survival until H&Y 3: 5.6 years vs. >10, p < 0.001; mini-mental state exam median decline 0.28 vs. 0.11, p < 0.001; and clinically recognized cognitive decline, p = 0.001). In real-world populations, patients are diagnosed more than eleven years later (RWD mean of 72.2 vs. research mean of 60.4, p < 0.001). After diagnosis, in real-world cohorts, treatment with PD medications has initiated an average of 2.3 years later (95% CI: [2.1-2.4]; p < 0.001). This study provides a detailed characterization of Parkinson's progression in diverse populations. It delineates systemic divergences in the patient populations enrolled in research settings vs. patients in the real-world. These divergences are likely due to a combination of selection bias and real population differences, but exact attribution of the causes is challenging. This study emphasizes a need to utilize multiple data sources and to diligently consider potential biases when planning, choosing data sources, and performing downstream tasks and analyses.

Identifiers

PMID38480700
PMCPMC10937726
OpenAlexW4392740577

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.